AIM ImmunoTech Inc. announced that the Netherlands Patent Office (Octrooicentrum Nederland) granted a utility patent covering rugged dsRNA, a double-stranded RNA product related to Ampligen(R) (rintatolimod), which claims cover, among other aspects, compositions and compositions for use in the prevention or treatment of COVID-19. The new patent broadens AIM's existing portfolio for COVID-19 treatments to include rugged dsRNA. Data from in vitro, pre-clinical and clinical experiments strongly suggest that Ampligen has a broad-spectrum early-onset antiviral effect by stimulating a powerful innate immune response.

The Company has conducted experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication.